• CSR Summary
• NCT01662310
• Primary Citation
• Data Specification

Approved Data Requests Associated with this Trial

• 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
• 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
• 2021-4823 : Long term risk for relapse in patients suffering from schizophrenia randomized to oral placebo - A historical prospective study
• 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
• 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
• 2021-4620 : The effects of antipsychotic discontinuation and reinstatement
• 2020-4517 : Metabolic side effects of antipsychotic drugs during medium- to long-term treatment in schizophrenia: Systematic review and network meta-analysis
• 2020-4175 : Placebo relapse after antipsychotic withdrawal: an individual participant meta-analysis
• 2019-3978 : Safety of Risperidone and Paliperdone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis
• 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
• 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
• 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
• 2017-1521 : Predictors of Relapse following Maintenance Treatment of Antipsychotic Drug or Placebo in patients with SCZ, schizoaffective disorder and BPD
• 2016-1005 : Identification of multivariate, clinical patterns predicting treatment response to paliperidone in schizophrenia
• 2016-0880 : Incidence of death and other SAEs related to second generation antipsychotic or placebo treatment in RCTs - a systematic review and meta-analysis